Soligenix Inc SNGX

NAS: SNGX | ISIN: US8342233074   14/11/2024
3,680 USD (+1,38%)
(+1,38%)   14/11/2024

3 september 2024 · Soligenix Receives European Patent for Improved Production of Synthetic Hypericin · Persbericht

9 augustus 2024 · Soligenix Announces Recent Accomplishments And Second Quarter 2024 Financial Results · Persbericht

9 juli 2024 · Expanded HyBryte™ Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma · Persbericht

25 juni 2024 · Soligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma · Persbericht

14 juni 2024 · A Comparison of Vaccine Technologies to be Presented at the ASM Microbe Conference · Persbericht

31 mei 2024 · Soligenix Announces Reverse Stock Split · Persbericht

29 mei 2024 · Soligenix Encourages Stockholders to Vote their Shares at the Annual Meeting · Persbericht

24 mei 2024 · Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting · Persbericht

23 mei 2024 · Soligenix Encourages Stockholders to Vote "FOR" Reverse Stock Split · Persbericht

21 mei 2024 · SuVax™ and MarVax™ Thermostable Vaccine Platform to be Presented at the Vaccine Technology IX Conference · Persbericht

20 mei 2024 · Soligenix Encourages Stockholders to Vote Prior to Annual Meeting · Persbericht

16 mei 2024 · Positive Clinical Results from HyBryte™ Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma Published in JEADV Clinical Practice · Persbericht

10 mei 2024 · Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial Results · Persbericht

6 mei 2024 · Soligenix to Present at Upcoming Conferences · Persbericht

25 april 2024 · Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa · Persbericht

18 april 2024 · Soligenix Announces Pricing of $4.75 Million Public Offering · Persbericht

15 april 2024 · FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection · Persbericht

11 april 2024 · FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection · Persbericht

3 april 2024 · Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency · Persbericht

15 maart 2024 · Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results · Persbericht

Mijn selecties